Zealand Pharma (Denmark) Executives
| ZEAL Stock | DKK 713.50 13.50 1.93% |
Zealand Pharma employs about 203 people. The company is managed by 10 executives with a total tenure of roughly 474 years, averaging almost 47.0 years of service per executive, having 20.3 employees per reported executive. Analysis of Zealand Pharma's management performance can provide insight into the firm performance.
| Henriette Wennicke Insider Chief Officer |
| Lani Morvan Insider Investor Officer |
Zealand |
Zealand Pharma Management Team Effectiveness
The company has return on total asset (ROA) of (0.4816) % which means that it has lost $0.4816 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.4412) %, meaning that it generated substantial loss on money invested by shareholders. Zealand Pharma's management efficiency ratios could be used to measure how well Zealand Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Zealand Pharma Workforce Comparison
Zealand Pharma AS is rated first in number of employees category among its peers. The total workforce of Biotechnology industry is at this time estimated at about 21,680. Zealand Pharma maintains roughly 203 in number of employees contributing less than 1% to stocks in Biotechnology industry.
Zealand Pharma AS Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Zealand Pharma AS Price Series Summation is a cross summation of Zealand Pharma price series and its benchmark/peer.
Zealand Pharma Notable Stakeholders
A Zealand Pharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Zealand Pharma often face trade-offs trying to please all of them. Zealand Pharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Zealand Pharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Henriette Wennicke | Chief Officer | Profile | |
| Lani Morvan | Investor Officer | Profile | |
| Adam MD | Pres CEO | Profile | |
| Hanne Bak | RD Director | Profile | |
| Mads Kronborg | Head Communication | Profile | |
| Ravinder Chahil | Sr Counsel | Profile | |
| Christina Bredal | VP Organization | Profile | |
| Danilo Verge | Head Affairs | Profile | |
| Ivan Moller | Chief Officer | Profile | |
| Jens MD | Head Pharmacology | Profile |
About Zealand Pharma Management Performance
The success or failure of an entity such as Zealand Pharma AS often depends on how effective the management is. Zealand Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Zealand management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Zealand management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Zealand Pharma AS, a biotechnology company, engages in the discovery, design, and development of peptide-based medicines in Denmark. The company was founded in 1997 and is headquartered in Copenhagen, Denmark. Zealand Pharma operates under Biotechnology classification in Denmark and is traded on Copenhagen Stock Exchange. It employs 360 people.
Zealand Pharma Workforce Analysis
Traditionally, organizations such as Zealand Pharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Zealand Pharma within its industry.Zealand Pharma Manpower Efficiency
Return on Zealand Pharma Manpower
| Revenue Per Employee | 1.4M | |
| Revenue Per Executive | 29.3M | |
| Net Loss Per Employee | 5M | |
| Net Loss Per Executive | 101.8M | |
| Working Capital Per Employee | 2.3M | |
| Working Capital Per Executive | 46.3M |
Other Information on Investing in Zealand Stock
Zealand Pharma financial ratios help investors to determine whether Zealand Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zealand with respect to the benefits of owning Zealand Pharma security.